Effects of homologous or heterologous antiserum on neutralizing-antibody response to rabies vaccine.
Heterologous antirabies serum is commonly used in the treatment of persons exposed to rabies. However, the high incidence of serum sickness which accompanies its use has prompted work to develop a homologous human product. As human antirabies serum is expensive and difficult to obtain in large quantities, a series of experiments was done on guinea-pigs to test the effects of homologous and heterologous antirabies serum.Similar amounts of homologous and heterologous antisera administered to guinea-pigs produced similar circulating neutralization titres one day later. The homologous antibody titres, however, decreased more slowly than the heterologous antibody titres.When homologous antiserum was given, followed by duck-embryo rabies vaccine, an apparent response to the vaccine was suppressed or delayed longer than when heterologous antiserum and vaccine were administered. However, when homologous antiserum was given with suckling-mouse-brain vaccine, of a much higher potency, the response to vaccine was apparent in the presence of a passive titre of 1:120.If a similar relationship is seen in man with the use of a homologous antirabies product, it will be essential to use high potency vaccines or alter the established vaccination schedules in order to overcome the inherent interference problems.
D000818:Animals; D006168:Guinea Pigs; D006801:Humans; D007106:Immune Sera; D051379:Mice; D011818:Rabies / Q000276:immunology; D011819:Rabies Vaccines
D007106:Immune Sera; D011819:Rabies Vaccines